US EditionMedtronic’s VenaSeal Evaluated in Spectrum Venous Leg Ulcer Study - Endovascular Today
Summary by Endovascular Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Medtronic’s VenaSeal Evaluated in Spectrum Venous Leg Ulcer Study - Endovascular Today
April 24, 2025—Medtronic announced the primary and secondary outcomes of the VenaSeal Spectrum Venous Leg Ulcer study. According to the company, the single-arm study prospectively assessed Medtronic’s VenaSeal closure system in patients with an active venous leg ulcer (classified as C6). The primary endpoint was time to ulcer healing after treatment with VenaSeal. The secondary endpoint was vein closure through 12 months. The podium-first presen…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
